Therapeutic strategy for atherosclerosis targeting for CETP
以CETP为靶点的动脉粥样硬化治疗策略
基本信息
- 批准号:12670712
- 负责人:
- 金额:$ 2.05万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2000
- 资助国家:日本
- 起止时间:2000 至 2002
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Background: CETP plays an important role in the reverse cholesterol transport. Inhibition of CETP activity by a CETP inhibitor, JTT-705, increases serum apo A-l levels and inhibits atherosclerosis. To clarify the mechanism by which CETP inhibition increases HDL levels, we examined the effects of JTT-705 on the in vivo kinetics properties of apo A-l in cholesterol-fed rabbits. Methods: Japanese White rabbits were randomly selected to be fed with (a) a normal rabbit chow, LRC-4 (n=10), (b) a diet containing 0.2% cholesterol (n=9), or (c) admixture of (b) and 0.75% JTT-705 (n=7) for 7 mo. CETP activities and serum levels of lipoproteins were measured. In vivo apo A-l kinetics was performed by injecting radioiodinated apo A-l at the end of the study. Results: JTT-705 inhibited 38.5% of the CETP activity in cholesterol-fed rabbits. Cholesterol-feeding decreased SR [8.3 ± 1.1 vs. 10.1 ± 1.8 mg/Kg/day] and serum levels of apo A-l and increased FCR [0.61 ± 0.07 vs. 0.52 ± 0.09 /day] compared with normal chow-feeding. JTT-705 normalized the reduced SR [11.2 ± 2.9 mg/Kg/day] and serum levels of apo A-l and the increased FCR [0.50 ± 0.06 /day] in cholesterol-fed rabbits. Conclusion: Inhibition of CETP activity favorably affects the lipoprotein metabolism in cholesterol-fed rabbits, suggesting that CETP inhibition may be a therapeutic approach for atherosclerosis.
背景:CETP在胆固醇逆向转运中起重要作用。CETP抑制剂JTT-705抑制CETP活性,增加血清载脂蛋白a - 1水平,抑制动脉粥样硬化。为了阐明抑制CETP增加HDL水平的机制,我们研究了JTT-705对胆固醇喂养家兔体内载脂蛋白a - 1动力学特性的影响。方法:随机选取日本大白兔,分别饲喂(a)正常兔粮LRC-4 (n=10)、(b)含0.2%胆固醇的日粮(n=9)或(c) (b)与0.75% JTT-705的混合物(n=7) 7个月,测定CETP活性和血清脂蛋白水平。体内载脂蛋白a - 1动力学在研究结束时通过注射放射性碘化载脂蛋白a - 1进行。结果:JTT-705对高胆固醇家兔CETP活性有38.5%的抑制作用。与正常喂养相比,胆固醇喂养降低了SR[8.3±1.1比10.1±1.8 mg/Kg/d]和血清载脂蛋白a - 1水平,增加了FCR[0.61±0.07比0.52±0.09 /d]。JTT-705使高胆固醇家兔SR(11.2±2.9 mg/Kg/day)和载脂蛋白a - 1 (apo a - 1)水平降低,FCR(0.50±0.06 mg/ day)升高。结论:抑制CETP活性有利于胆固醇喂养家兔的脂蛋白代谢,提示抑制CETP可能是一种治疗动脉粥样硬化的方法。
项目成果
期刊论文数量(32)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
朔啓二郎: "HDL代謝と虚血性心臓病"臨床と研究. 78巻1号. 135-139 (2001)
Keijiro Saku:“HDL 代谢与缺血性心脏病”,《临床与研究》,第 78 卷,第 1. 135-139 期(2001 年)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Aoki J, Taira A, Takanezawa Y, Kishi Y, Hama K, Kishimoto T, Mizuno K, Saku K, Taguchi A, Arai H.: "Serum lysophosphatidic acid is produced through diverse phospholipase pathways"J Biol Chem.. 277. 48737-48744 (2002)
Aoki J、Taira A、Takanezawa Y、Kishi Y、Hama K、Kishimoto T、Mizuno K、Saku K、Taguchi A、Arai H.:“血清溶血磷脂酸是通过多种磷脂酶途径产生的”J Biol Chem.. 277. 48737
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Zhang B, Shimoji E, Tanaka H, Saku K: "Evaluation of apolipoprotein A-l kinetics in rabbits in vivo using in situ and exogeneous radioiodination methods"Lipid. in press. (2003)
张 B、Shimoji E、田中 H、Saku K:“使用原位和外源放射性碘标记方法评估兔子体内载脂蛋白 A-l 动力学”脂质。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Nomoto J, Oku K, Takao M, Tahara H, Inoue T, Handa K, Arakawa K, Saku K: "Left arterial thrombus formation in patients with nonvalvular paroxysmal atrial fibrillation"Med Bull Fukuoka Univ.. 29(4). 187-194 (2002)
Nomoto J,Oku K,Takao M,Tahara H,Inoue T,Handa K,Arakawa K,Saku K:“非瓣膜性阵发性心房颤动患者的左动脉血栓形成”Med Bull Fukuoka Univ.. 29(4)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Saku K.,Zhang B.,Arakawa K.: "High-density lipoprotein as an indicator of CAD."Cardiology Review.. 17. 25-30 (2000)
Saku K.、Zhang B.、Arakawa K.:“高密度脂蛋白作为 CAD 的指标。”心脏病学评论.. 17. 25-30 (2000)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SAKU Keijiro其他文献
SAKU Keijiro的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SAKU Keijiro', 18)}}的其他基金
New diagnostic and therapeutic strategies for atherosclerosis using newly developed apolipoprotein A-I mimetic peptide
使用新开发的载脂蛋白 A-I 模拟肽治疗动脉粥样硬化的新策略
- 批准号:
24591123 - 财政年份:2012
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Possibility of drug discovery : Development of new peptide type of reconstituted HDL
药物发现的可能性:开发重组 HDL 的新肽类型
- 批准号:
21590960 - 财政年份:2009
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Advanced medical technology on cardiovascular disease- Elucidation of the molecular mechanism and the application on various pathological conditions for the establishment of HDL therapy
心血管疾病先进医疗技术-阐明HDL疗法的分子机制及其在多种病理条件下的应用
- 批准号:
18590826 - 财政年份:2006
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Quality, function and genetic assessments of NO, ACE and HDL in patients with coronary artery disease
冠状动脉疾病患者 NO、ACE 和 HDL 的质量、功能和遗传评估
- 批准号:
09670773 - 财政年份:1997
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Quantity, function and genetics of HDL as an indicator of CHD.
HDL 的数量、功能和遗传学作为 CHD 的指标。
- 批准号:
07670827 - 财政年份:1995
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
HDL-apoAI gene expression and its kinetics in vivo
HDL-apoAI基因表达及其体内动力学
- 批准号:
04671503 - 财政年份:1992
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
HDL-apoAI and its isoproteins kinetics in rabbits and gene expressin of apoAI.
HDL-apoAI 及其同种蛋白在兔体内的动力学及 apoAI 基因表达。
- 批准号:
02671114 - 财政年份:1990
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)